AOD-9604 vs Tesamorelin: Which Fat-Loss Peptide Has Real Evidence?
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-20
A failed obesity drug vs an FDA-approved visceral-fat peptide — compared on evidence, cost, and access
AOD-9604 is a GH-fragment peptide that failed its Phase III obesity trial and is sold only as an unregulated research chemical. Tesamorelin (Egrifta) is an FDA-approved GHRH analog with Phase III trial data showing 15-25% visceral fat reduction. The evidence gap between them is the whole story.
This article is for informational purposes only and is not medical advice. Consult a physician before starting, stopping, or combining any peptide or prescription medication.
AOD-9604 and tesamorelin both get grouped together as "fat-loss peptides," and people researching one frequently ask about the other — including whether the two can be stacked. But they sit on opposite ends of the evidence spectrum: one failed its pivotal human trial, the other is FDA-approved on the strength of its own Phase III data.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →This comparison covers mechanism, trial results, cost, access, and the stacking question directly, using the same evidence already detailed in our AOD-9604 guide.
AOD-9604 vs Tesamorelin at a Glance
AOD-9604 and tesamorelin are both growth-hormone-derived compounds aimed at fat loss, but they diverge completely on regulatory status and trial outcome.| Dimension | AOD-9604 | Tesamorelin |
|---|---|---|
| Mechanism | Isolated lipolytic fragment (amino acids 176-191) of growth hormone | GHRH analog — stimulates the pituitary to release the body's own GH |
| FDA status | Not approved; GRAS (food-ingredient) status only, granted 2020 | Approved 2010 for HIV-associated lipodystrophy, sold as Egrifta |
| Pivotal trial result | Phase III failed — no significant weight loss vs. placebo over 24 weeks | Phase III succeeded — 15-25% visceral fat reduction in RCTs |
| Target effect | General subcutaneous fat loss (unproven in humans) | Visceral (abdominal) fat specifically |
| Access | Unregulated research chemical | Prescription required; limited compounding availability |
| Monthly cost | $30-60 (research-grade) | $3,000-5,000 (brand Egrifta) |
| Half-life | Short; typically dosed once daily | ~26 minutes |
Why the Trial Outcomes Diverge So Sharply
AOD-9604 and tesamorelin failed and succeeded, respectively, for reasons tied directly to how each was designed and tested. AOD-9604's Phase IIb/III obesity trial found no statistically significant weight loss versus placebo over 24 weeks of oral dosing — the compound never cleared the bar its own developer set for it. Tesamorelin's Phase III program, by contrast, was designed around a narrower, better-defined endpoint — visceral fat reduction in a specific patient population (HIV-associated lipodystrophy) — and it met that endpoint, which is why it carries FDA approval today.
The practical takeaway: AOD-9604's evidence problem isn't that it was tested and found modestly effective — it's that the controlled trial found no effect distinguishable from placebo. Tesamorelin's approval reflects an actual positive trial result, not just GRAS food-safety clearance.
Can You Stack AOD-9604 and Tesamorelin?
Some users do combine AOD-9604 with tesamorelin, reasoning that one targets general lipolysis while the other targets visceral fat through a completely different mechanism (GHRH-stimulated GH release vs. an isolated GH fragment). No controlled trial has tested this specific combination, so any reported benefit is anecdotal.
Because tesamorelin already has controlled trial evidence on its own, adding AOD-9604 — a compound that failed its own placebo-controlled trial — does not add proven value to the stack. Anyone considering prescription tesamorelin should discuss any additional compound with their prescribing physician first.
Which Should You Consider?
Tesamorelin fits if: you have HIV-associated lipodystrophy (its FDA-indicated use), visceral fat reduction is the specific goal, and cost is not the primary barrier.
AOD-9604 fits if: honestly, the evidence doesn't support it as a primary choice for anyone. See our full AOD-9604 review for the complete trial history and better-evidenced alternatives, including CJC-1295 + ipamorelin for cost-conscious body recomposition.
Frequently Asked Questions
Is tesamorelin better than AOD-9604?
On the evidence, yes. Tesamorelin has Phase III RCT data supporting 15-25% visceral fat reduction and carries FDA approval for HIV-associated lipodystrophy. AOD-9604's own Phase III obesity trial found no significant weight loss versus placebo. Tesamorelin's FDA-approval reflects a positive trial result; AOD-9604's GRAS status is a food-safety classification, not an efficacy finding.
Can AOD-9604 and tesamorelin be taken together?
Some users self-stack the two, but no controlled trial has tested this combination, so any benefit is anecdotal. Tesamorelin already has its own positive trial data; adding AOD-9604 does not add proven benefit. Anyone on prescription tesamorelin should check with their physician before adding any other compound.
Why does tesamorelin cost so much more than AOD-9604?
Tesamorelin is a patented, FDA-approved prescription drug (brand name Egrifta) that went through the full clinical trial and regulatory approval process, which is reflected in its $3,000-5,000/month brand price. AOD-9604 is sold as an unregulated research chemical with no development, trial, or regulatory costs behind its $30-60/month price — the price gap tracks the evidence gap.
Do AOD-9604 and tesamorelin work the same way?
No. AOD-9604 is an isolated fragment (amino acids 176-191) of growth hormone believed to carry only its fat-burning activity. Tesamorelin is a GHRH analog that stimulates the pituitary gland to release the body's own growth hormone. The mechanisms are related — both touch the GH pathway — but they are not interchangeable.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
AOD-9604 vs HGH Fragment 176-191: Are They the Same Peptide?
AOD-9604 vs HGH Fragment 176-191: naming confusion, history, and what the evidence shows.
-
AOD-9604 vs Tirzepatide: Research Peptide vs FDA-approved Weight Loss Drug
AOD-9604 vs tirzepatide: unproven research peptide vs FDA-approved GLP-1 weight-loss drug.
-
AOD-9604 vs MOTS-c: Comparing Two Unproven Research Peptides
AOD-9604 vs MOTS-c: comparing two unproven research peptides with different target claims.
See more related comparisons
-
AOD-9604: the Fat-loss Peptide That Failed Phase III — and What Works Instead
AOD-9604: the GH fragment that failed Phase III, why it's still sold, and what actually works for fat loss.
-
Tesamorelin vs Sermorelin
Tesamorelin vs sermorelin: GH peptide differences, use cases, and which to choose.
-
CJC-1295 vs Tesamorelin: FDA-approved GHRH Analog vs Longer-acting Unapproved Option
CJC-1295 vs tesamorelin: FDA-approved GHRH analog vs longer-acting unapproved option.
-
Tesamorelin vs Ipamorelin: GHRH Analog vs Selective GHRP Compared
Tesamorelin vs ipamorelin: GHRH analog vs selective GHRP, often combined not substituted.